Iterum Therapeutics plc (ITRMF) Cash from Operations (2017 - 2025)

Iterum Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 7447000.0 for Q3 2025.

• In Q3 2025, Cash from Operations fell 178.71% year-over-year to 7447000.0; the TTM figure through Sep 2025 stood at 19514000.0 (up 44.81% YoY), while the FY2024 annual figure was 26770000.0, up 31.93% from the prior year.
• Cash from Operations for Q3 2025 stood at 7447000.0, down from 4751000.0 in the prior quarter.
• The five-year high for Cash from Operations was 1132000.0 in Q1 2021, with the low at 13083000.0 in Q1 2024.
• The 5-year median for Cash from Operations is 4751000.0 (2025), against an average of 6088052.63.
• The sharpest annual moves came in 2021 and 2023: Cash from Operations soared 95.87% in 2021, then tumbled 201.13% in 2023.
• Iterum Therapeutics' Cash from Operations stood at 2459000.0 in 2021, then sank by 73.44% to 4265000.0 in 2022, then sank by 201.13% to 12843000.0 in 2023, then soared by 66.86% to 4256000.0 in 2024, then tumbled by 74.98% to 7447000.0 in 2025.
• Business Quant data shows ITRMF's Cash from Operations at 7447000.0 in Q3 2025, 4751000.0 in Q2 2025, and 3060000.0 in Q1 2025.